title: Analysis of serum CYFRA 21-1 concentrations in patients with esophageal cancer.
abstract: BACKGROUND
  This study was conducted to determine the use of CYFRA 21-1 for patients suffering from esophageal carcinoma.
  
  
  METHODS
  50 patients with malignant, 50 patients with benign esophageal lesions, 50 healthy persons and 50 patients with benign lung disease were tested for CYFRA 21-1, CEA, CA 72-4 and SCC-antigen serum concentrations. The patients with esophageal carcinoma underwent follow-up analysis for one year.
  
  
  RESULTS
  CYFRA 21-1 (cut-off: 1.40 ng/ml) showed a sensitivity for esophageal carcinoma of 46% at a specificity of 89.3%. There was a tendency for higher serum CYFRA 21-1 concentrations in advanced T-stages. Correlations of CYFRA 21-1 with N or M stages could not be observed. The postoperative course, in terms of survival and tumor free survival showed significant correlation to pre-operative CYFRA 21-1 concentrations. Adjuvant therapy could be monitored by CYFRA 21-1 as well. Clinical tumor recurrence was preceded by CYFRA 21-1 elevation by 3.4 months.
  
  
  CONCLUSIONS
  We recommend the use of CYFRA 21-1 in cases of esophageal carcinoma, especially in cases of squamous cell carcinoma.
authors.affiliation: Klinik und Poliklinik für Allgemeine Chirurgie der Westfälischen Wilhelms-Universität Münster, Waldeyerstr, 1, 48149 Münster, Germany. brockmj@uni-muenster.de
authors.forename: J G
authors.initials: JG
authors.lastname: Brockmann
authors.forename: H
authors.initials: H
authors.lastname: St  Nottberg
authors.forename: B
authors.initials: B
authors.lastname: Glodny
authors.forename: B
authors.initials: B
authors.lastname: Sprakel
authors.forename: N
authors.initials: N
authors.lastname: Senninger
mesh_terms: D000951:Antigens, Neoplasm / Q000097:blood*; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood; D004938:Esophageal Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000401:mortality; D006801:Humans; D053539:Keratin-19; D007633:Keratins; D011379:Prognosis; D015843:Serpins; D015996:Survival Rate
chemical_list: D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; C083825:CA-72-4 antigen; D002272:Carcinoembryonic Antigen; D053539:Keratin-19; D015843:Serpins; C102012:antigen CYFRA21.1; C051072:squamous cell carcinoma-related antigen; D007633:Keratins